President Trump on Thursday sent letters to 17 of the world’s biggest drugmakers demanding that they reduce some of their U.S. prices to the much lower levels they charge other wealthy countries by ...

Tempus AI's 10% dip reveals an opportunity as Q2 estimates are poised to exceed expectations, fueled by strong deals and ...

Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.

Dan Lefkovitz of Morningstar I recently interviewed investor and author Daniel Rasmussen for The Long View podcast, where he ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

AstraZeneca's efforts are paying off as strong U.S. demand, and robust sales of newer cancer, heart and kidney disease ...

Novo Nordisk's new CEO, Maziar Mike Doustdar, faces challenges in reviving waning sales and shares in the weight-loss drug ...

Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

AstraZeneca PLC (NASDAQ:AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) announced ...